Habboushe

Joseph Habboushe, New York, NY US

Patent application number	Description	Published
20100292714	SKIN MARKING DEVICE AND SUTURE HOLDER - A skin marking device can include two or more skin marking members and a holding member coupled with the two or more skin marking members. The holding member can include at least one adjustment assembly. The adjustment assembly can adjust at least one of width or length between the skin marking members. In an example, a suture holder device can include a base and a member coupled with the base. The member can include one or more suture assembly holders. At least one attachment can be coupled with the base. The attachment can be adapted to couple the suture holder device with other structure.	11-18-2010

Patent application number	Description	Published
20090279708	ELECTRONIC STETHOSCOPE APPARATUS - An electronic stethoscope system that reduces cross-infection when examining a patient is provided. The electronic stethoscope system includes a handheld auscultation portion for picking up bodily sounds of a patient. The detected bodily sounds are transmitted to a base unit having a loudspeaker for broadcasting an audible representation of the detected bodily sounds. The sounds are transmitted to the base unit either by a wireless transmitter and receiver or by way of a disposable flexible tubing adapted for transmitting acoustic waves.	11-12-2009

Patent application number	Description	Published
20100166810	COMBINATION TABLET WITH CHEWABLE OUTER LAYER - A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.	07-01-2010